TrimRx's Blog

Yes, Wegovy (semaglutide 2.4 mg) is FDA-approved for adolescents aged 12 and older with obesity, and Saxenda has been approved for teens since 2020.

The short answer is that no human study has tested this combination, so any claim of safety or efficacy is theoretical.

The thymosin beta-4 literature is in better shape than the BPC-157 literature in several ways.

Thymosin beta-4 is one of the better-characterized small peptides in cell biology, which is unusual for the regenerative peptide category.

There is no FDA-approved dose for systemic injectable TB-500 because there is no FDA-approved indication.

TB-500 is a synthetic peptide based on a fragment of thymosin beta-4, a 43-amino-acid protein found naturally in nearly every cell of the human body.

There’s no FDA-approved taper protocol for semaglutide or tirzepatide. The label says to stop the medication, that’s it.

There’s no script for this.

Switching from Zepbound to compounded tirzepatide is clinically simple when the compounded product uses tirzepatide base API at accurate potency.